TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04087915
Drug: Evolocumab
Normalized name: Evolocumab
DrugBank: Evolocumab (DB09303)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants received evolocumab 140 mg Q2W or 420 mg QM subcutaneous injections according to their own preference
Study: NCT01255137
Drug: Axitinib
Normalized name: Axitinib
DrugBank: Axitinib (DB06626)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5 mg tab orally twice a day with food every 28 days
Study: NCT00399633
Drug: sumatriptan
Normalized name: Sumatriptan
DrugBank: Sumatriptan (DB00669)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00282451
Drug: biphasic insulin aspart
Normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00282451
Drug: insulin aspart
Normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT01696760
Drug: enoxaparin
Normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg once daily
Study: NCT01267487
Drug: PO continuous infusion of Protamine
Normalized name: protamines
DrugBank: Protamine sulfate (DB09141)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 25mg/hour in IV continuous infusion during first 6 PO hours
Study: NCT01332292
Drug: Fluticasone furoate
Normalized name: Fluticasone Furoate
DrugBank: Fluticasone furoate (DB08906)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Novel dry powder inhaler: 100µg per blister One blister strip containing fluticasone furoate micronised drug blended with lactose and a second blister strip containing lactose and magnesium stearate.
Study: NCT04542057
Drug: Ensifentrine
Normalized name: Ensifentrine
DrugBank: Ensifentrine (DB16157)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosage Formulation:~Ensifentrine Nebulizer suspension Dosage 3mg Frequency: Twice Daily for 24 weeks
Study: NCT00352417
Drug: VIA-2291
Normalized name: Human parathyroid hormone (PTH) synthetic peptide fragment (1-34), conjugated at the N-terminal amino group via a cleavable linker to O-methylpolyethylene glycol (2 x 20 kDa mPEG); 2-methylalanyl-(1-34)-peptide of parathyroid hormone (Homo sapiens parath
DrugBank: Palopegteriparatide (DB18676)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg, oral dosing, 1 time daily for 12 weeks
Study: NCT00396565
Drug: ER OROS paliperidone
Normalized name: paliperidone Extended Release Oral Tablet
DrugBank: Paliperidone (DB01267)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Type= exact number, unit= mg, number= 3, form= tablet, route= oral use. Two tablets once daily for 6 weeks.
Study: NCT00396565
Drug: Olanzapine
Normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Type= exact number, unit= mg, number= 2.5, form= tablet, route= oral use. Four tablets once daily for 6 weeks.
Study: NCT03910673
Drug: Fosfomycin disodium
Normalized name: fosfomycin disodium
DrugBank: Fosfomycin (DB00828)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fosfomycin (a phosphonic acid derivative) formulated as a disodium salt.
Study: NCT01029743
Drug: Rivaroxaban (Xarelto, BAY59-7939)
Normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Daily dose, a treatment duration of 5 weeks for patients undergoing major hip surgery and a treatment duration of 2 weeks for patients undergoing major knee surgery are recommended
Study: NCT01029743
Drug: Pharmacologic agents (e.g. LMWH/VKA/Fondaparinux/Aspirin and etc.)
Normalized name: Fondaparinux
DrugBank: Fondaparinux (DB00569)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Daily dose, dosage frequency and duration will be decided by physicians
Study: NCT04077580
Drug: Methenamine Hippurate 1000 MG
Normalized name: methenamine hippurate 1000 MG
DrugBank: Methenamine (DB06799)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methenamine and placebo is taken 1 tablet morning and evening for 180 days
Study: NCT00321191
Drug: No nitrous oxide
Normalized name: Nitrous Oxide
DrugBank: Nitrous oxide (DB06690)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00321191
Drug: Administration of N2O
Normalized name: N2O
DrugBank: Nitrous oxide (DB06690)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01675648
Drug: Lofexidine
Normalized name: LOFEXIDINE
DrugBank: Lofexidine (DB04948)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01675648
Drug: Diazepam
Normalized name: Diazepam
DrugBank: Diazepam (DB00829)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02698111
Drug: Donafenib
Normalized name: DONAFENIB
DrugBank: CM-4307 (DB15414)
Approvals — FDA: no, EMA: no, PMDA: no
Description: donafenib 200mg，bid
Study: NCT04511819
Drug: Losmapimod oral tablet
Normalized name: Losmapimod
DrugBank: Losmapimod (DB12270)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losmapimod will be administered with food when possible.
Study: NCT00893269
Drug: eszopiclone
Normalized name: Eszopiclone
DrugBank: Eszopiclone (DB00402)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral capsule at dose recommended for adults
Study: NCT00893269
Drug: ramelteon
Normalized name: Ramelteon
DrugBank: Ramelteon (DB00980)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ramelteon
Study: NCT00893269
Drug: zolpidem
Normalized name: Zolpidem
DrugBank: Zolpidem (DB00425)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: zolpidem
Study: NCT00000384
Drug: Sertraline
Normalized name: Sertraline
DrugBank: Sertraline (DB01104)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01940510
Drug: rifampin
Normalized name: Rifampin
DrugBank: Rifampin (DB01045)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple doses Days 8-16 and Days 17-20
Study: NCT00003225
Drug: amifostine trihydrate
Normalized name: Amifostine
DrugBank: Amifostine (DB01143)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ethyol 740 mg/m2 will be administered intravenously over 10 minutes. Administered every two weeks for 3 cycles.
Study: NCT00003225
Drug: irinotecan hydrochloride
Normalized name: Irinotecan Hydrochloride
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 10 minutes after completion of the Ethyol infusion, Irinotecan 250 mg/m2 will be given over 90 minutes IV.~Administered every 14 days for 3 cycles
Study: NCT02060318
Drug: Infliximab
Normalized name: Infliximab
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: The patients are included in the study when the decision to treat with Infliximab is already made. This study is observational, and all treatment and clinical follow-up are according to national guidelines.
Study: NCT03247413
Drug: Dexamethasone 4 mg/ml
Normalized name: dexamethasone 4 MG/ML
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: dexamethasone 4 milligram given post-ablation at each lesion site
Study: NCT06742216
Drug: Monosialoganglioside
Normalized name: Monosialoganglioside GM1 antibody
DrugBank: Ganglioside GM1 (DB16948)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monosialoganglioside diluted with 0.9% normal saline 100ml, iv, daily for 12-14 days
Study: NCT03277755
Drug: AL-335 800 mg
Normalized name: Al
DrugBank: Aluminium (DB01370)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive AL-335 800 mg (2 tablets of 400 mg AL-335) single oral dose on Day 1 of part 1 and in combination as AL-335 + ODV + SMV once daily orally from Day 1 to 14 of part 2.
Study: NCT03277755
Drug: ODV 25 mg
Normalized name: ODV
DrugBank: Desvenlafaxine (DB06700)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will receive ODV 25 mg (1 tablet of 25 mg ODV) single oral dose on Day 8 of part 1 and in combination as AL-335 + ODV + SMV once daily orally from Day 1 to 14 of part 2.
Study: NCT03414684
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin interferes with the development of the genetic material in a cell, which will cause the cancer cells to die.
Study: NCT03414684
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nivolumab works by attaching to and blocking a molecule called PD-1. PD-1 is a different molecule that can turn off the immune system by interacting with PD-L1 on the cancer cells
Study: NCT02852577
Drug: Clonazepam
Normalized name: Clonazepam
DrugBank: Clonazepam (DB01068)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administration of clonazepam once a day, flexible dose (0.5 - 2 mg/day), for 36 months. If no remission after 8 weeks augmentation with paroxetine once a day, flexible dose (10 - 40 mg/day), for 34 months.
Study: NCT02852577
Drug: Paroxetine
Normalized name: Paroxetine
DrugBank: Paroxetine (DB00715)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administration of paroxetine once a day, flexible dose (10 - 40 mg/day), for 36 months. If no remission after 8 weeks augmentation with clonazepam once a day, flexible dose (0.5 - 2 mg/day), for 34 months.
Study: NCT01028482
Drug: Sertraline
Normalized name: Sertraline
DrugBank: Sertraline (DB01104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: group A- sertraline 50-100 mg/day and weekly psychotherapy for 3 months~group B- weekly psychotherapy- for 3 months~group C- sertraline 50-100 mg/day-for 3 months
Study: NCT03101176
Drug: SonoVue
DrugBank: Sulfur hexafluoride (DB11104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The ultrasound contrast agent used for the CEUS specific ultrasound mode
Study: NCT00370240
Drug: Chlorhydrate de Ropivacaine
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The Ropivacaïne group received 3mg/kg of 0.375% ropivacaïne(0.75% ropivacaïne, Astra, mixed with saline)
Study: NCT00036192
Drug: FK614
Normalized name: Fexofenadine
DrugBank: Fexofenadine (DB00950)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00641446
Drug: budesonide
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00641446
Drug: varicella zoster virus
Normalized name: varicella zoster virus glycoprotein E
DrugBank: Rice (DB10563)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02653833
Drug: Tadalafil 20 MG
Normalized name: tadalafil 20 MG
DrugBank: Tadalafil (DB00820)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Blood flow to the forearm is visualized via an ultrasound technique at rest and with graded exercise. The experiment is then repeated shortly after the subject takes the study agent, beetroot juice extract.
Study: NCT02129608
Drug: Lorcaserin
Normalized name: Lorcaserin
DrugBank: Lorcaserin (DB04871)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10 mg pills twice daily for 12 weeks.
Study: NCT03551821
Drug: ATI-50002
Normalized name: ATI-355
DrugBank: ATI-355 (DB17923)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical Solution
Study: NCT02678208
Drug: Tranexamic Acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02678208
Drug: 5% glucose
Normalized name: Dextrose/Water 5% Oral Solution [ENFAMIL 5% GLUCOSE IN WATER]
DrugBank: Water (DB09145)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03624920
Drug: THN102 Dosage A
Normalized name: osage orange pollen extract
DrugBank: Sage (DB10982)
Approvals — FDA: no, EMA: no, PMDA: no
Description: THN102 Dosages A: placebo
Study: NCT03624920
Drug: THN102 Dosage B
Normalized name: hepatitis B surface antigen vaccine
DrugBank: Sage (DB10982)
Approvals — FDA: no, EMA: no, PMDA: no
Description: THN102 Dosage B : 200mg/2mg
Study: NCT03624920
Drug: THN102 Dosage C
Normalized name: Vitamin C
DrugBank: Sage (DB10982)
Approvals — FDA: no, EMA: no, PMDA: no
Description: THN102 Dosage C: 200mg/18mg
Study: NCT02299063
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: A bolus dose of 0.5 mcg/kg infused over 10 minutes will be administered, followed by a continuous infusion for the duration of the surgery at 0.6 mcg/kg/hr.
Study: NCT06750445
Drug: Polyethylene Glycol 400 0.4%
Normalized name: Polyethylene Glycol 400 0.4%, Propylene Glycol 0.3% Ophthalmic drops, solution
DrugBank: Polyethylene glycol (DB09287)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The control group (PEG) used polyethylene glycol as a rescue medication under the same conditions, following similar monitoring and follow-up procedures.
Study: NCT02097433
Drug: Dacomitinib
Normalized name: DACOMITINIB
DrugBank: Dacomitinib (DB11963)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: A single 45 mg oral dose of Dacomitinib will be administered under fasted conditions to healthy Chinese volunteers
Study: NCT00516425
Drug: epirubicin hydrochloride
Normalized name: Epirubicin Hydrochloride
DrugBank: Epirubicin (DB00445)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02068131
Drug: Novaferon
Normalized name: Novaferon
DrugBank: Novaferon (DB16483)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant anti-tumor and anti-virus protein for injection, 10μg, im, 3 times per week for first 2 weeks, followed by 20μg,im, 3 times per week after 2 weeks.
Study: NCT03508635
Drug: CORT125134
Normalized name: CORT125134
DrugBank: Relacorilant (DB14976)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral capsules
Study: NCT03508635
Drug: Mifepristone
Normalized name: Mifepristone
DrugBank: Mifepristone (DB00834)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Active comparator
Study: NCT03508635
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Challenge agent
Study: NCT03508635
Drug: Glucose
Normalized name: Glucose
DrugBank: Dextrose, unspecified form (DB09341)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02656069
Drug: Lilly Glucagon (glucagon injection [rDNA origin])
Normalized name: Glucagon
DrugBank: Glucagon (DB00040)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 1 mg of Lilly glucagon reconstituted from lyophilized powder
Study: NCT01905436
Drug: Annual versus Semiannual Albendazole plus Ivermectin Mass Drug Administration
Normalized name: Albendazole
DrugBank: Albendazole (DB00518)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Annual or semiannual Albendazole plus Ivermectin, administered by the Liberian Ministry of Health.
Study: NCT04152863
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered as an IV infusion of 200 mg
Study: NCT04303780
Drug: AMG 510
Normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 21 day cycles
Study: NCT04303780
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 21 day cycles
Study: NCT00738257
Drug: Pamidronate
Normalized name: Pamidronate
DrugBank: Pamidronic acid (DB00282)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01485822
Drug: Travoprost 0.004% ophthalmic solution
Normalized name: Travoprost 0.004% Ophthalmic Solution
DrugBank: Travoprost (DB00287)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT03377257
Drug: zolmitriptan by sublingual administration
Normalized name: Zolmitriptan
DrugBank: Zolmitriptan (DB00315)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Experimental group
Study: NCT03377257
Drug: zolmitriptan by oral
Normalized name: Zolmitriptan
DrugBank: Zolmitriptan (DB00315)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Active group
Study: NCT00071422
Drug: INGAP-Peptide
Normalized name: peptide-T
DrugBank: Peptide-T (DB19279)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mL, once daily, self-administered SC injection for 90 days
Study: NCT00250991
Drug: activase
Normalized name: Activase
DrugBank: Alteplase (DB00009)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00250991
Drug: integrilin
Normalized name: Integrilin
DrugBank: Eptifibatide (DB00063)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00976950
Drug: Tipranavir
Normalized name: Tipranavir
DrugBank: Tipranavir (DB00932)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00976950
Drug: ritonavir
Normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: low-dose
Study: NCT01160341
Drug: Testosteron
Normalized name: Testosteron
DrugBank: Testosterone (DB00624)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosteron 250mg injection per 3-4 weeks for 6 months
Study: NCT01947959
Drug: Rivaroxaban (Xarelto, Bay59-7939)
Normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: The treatment of DVT or PE, and prevention of recurrent DVT and PE in adult patients (15 mg rivaroxaban twice daily \[bid\] for 3 weeks, then 15 mg or 20 mg once daily \[od\], tablets).~The prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (stroke prevention in atrial fibrillation \[SPAF\]) with one or more risk factors (20 mg rivaroxaban \[od\], tablets).~The prevention of venous thromboembolism (VTE) in adult patients undergoing elective hip or knee replacement surgery (recommended dose: 10 mg rivaroxaban \[od\] tablets for 35 days following hip replacement surgery and 14 days following knee replacement surgery).~Co-administered with acetylsalicylic acid (ASA) alone or with ASA plus clopidogrel or ticlopidine, for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (ACS) with elevated cardiac biomarkers (recommended dose 2.5 mg rivaroxaban tablets \[bid\]).
Study: NCT02129322
Drug: Sorafenib
Normalized name: Sorafenib
DrugBank: Sorafenib (DB00398)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02129322
Drug: S-1
Normalized name: LIS-1
DrugBank: Tegafur (DB09256)
Approvals — FDA: no, EMA: yes, PMDA: no
Study: NCT02129322
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03391414
Drug: hypertonic bicarbonate
Normalized name: Potassium Bicarbonate
DrugBank: Potassium bicarbonate (DB11098)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8.4% sodium bicarbonate inhaled
Study: NCT03391414
Drug: sodium chloride
Normalized name: Sodium Chloride
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 7% sodium chloride inhaled
Study: NCT01721317
Drug: Ezogabine/Retigabine IR
DrugBank: Ezogabine (DB04953)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects received drug (dose strength 300 mg to 1200 mg) orally with or without food. The 3 daily doses are to be administered with approximately an 8-hour interval between them.
Study: NCT01044108
Drug: NNC 0070-0002-0453
Normalized name: NNC-55-0396 free base
DrugBank: NNC-55-0396 free base (DB17037)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of a single subcutaneous (under the skin) dose. Up to 7 escalating dose levels will be investigated. Progression to next dose level will be based on a safety evaluation.
Study: NCT00195455
Drug: Trimegestone
Normalized name: trimegestone
DrugBank: Trimegestone (DB13129)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00999817
Drug: reference [dextromethorphan]
DrugBank: Dextromethorphan (DB00514)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: single 30 mg oral dose
Study: NCT00959218
Drug: Dronabinol
Normalized name: Dronabinol
DrugBank: Dronabinol (DB00470)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral solution, daily dose up to 15 mg, treatment up to 2.5 years
Study: NCT00979641
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02876718
Drug: Rivaroxaban (Xarelto, BAY 59-7939)
Normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: No specified dosing or dosage in the study. The treatment decision falls within current practice and the prescription of the medicines is clearly separated from the decision to include the patient in the study.
Study: NCT00534456
Drug: Darbepoetin alfa
Normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Starting dose: 0.75 mcg/kg subcutaneously Q2W. Subsequent doses: Darbepoetin alfa group to receive darbepoetin alfa titrated to achieve Hb target of 13.0 g/dL, not to exceed 14.5 g/dL.
Study: NCT03302208
Drug: Pregabalin
Normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pregabalin capsule 150 mg oral
Study: NCT01875367
Drug: Trastuzumab Injectable Solution
Normalized name: trastuzumab Injectable Solution
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subcutaneous injection vial with a fixed dose of trastuzumab (600mg) and recombinant human hyaluronidase (10.000U) identical to that provided by the device. 3 weeks x 2 cycles.
Study: NCT01875367
Drug: Trastuzumab Injectable Product
Normalized name: trastuzumab Injectable Product
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Single injection device is provided and loaded with the mixture of trastuzumab (600mg) and recombinant human hyaluronidase (10.000U) and is ready for use. 3 weeks x 2 cycles
Study: NCT01875367
Drug: Trastuzumab Injection
Normalized name: trastuzumab Injection
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Powder for concentrate for solution for infusion. 1 cycle
Study: NCT02258867
Drug: Gevokizumab
Normalized name: Gevokizumab
DrugBank: Gevokizumab (DB12119)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution for subcutaneous injection
Study: NCT02531932
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin will be administered if ANC \> 1.0 and platelets are \>75k
Study: NCT02531932
Drug: Everolimus
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: The study drug Everolimus will be self-administered (by the patients themselves).
Study: NCT02587078
Drug: Jonosteril
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients who meet the inclusion criteria (at Screening, see below for definition) will be randomized immediately in a ratio of 1:1 to either intravenous Volulyte® or Jonosteril® for fluid resuscitation (on RAND). Fluid resuscitation with study drug will be started immediately in order to reach initial hemodynamic stabilization.
Study: NCT00444587
Drug: trastuzumab [Herceptin]
DrugBank: Trastuzumab emtansine (DB05773)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 6mg/kg iv every 3 weeks
Study: NCT03512873
Drug: Tranilast
Normalized name: Tranilast
DrugBank: Tranilast (DB07615)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will be treated with tranilast
Study: NCT04170465
Drug: Metformin Hydrochloride 850 mg Tablets
Normalized name: metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Oral administration of Metformin hydrochloride 850 mg tablets (1700 mg/day) daily until the completion of neoadjuvant chemotherapy cycles